Cabaletta Bio Inc (CABA) News

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

– CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients;...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the...

Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage...

Form 8-K - Current report

Form 8-K - Current report

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

PHILADELPHIA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage...

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

PHILADELPHIA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

– Nine patients enrolled as of August 5, 2024 across the RESET™ clinical development program, including four...

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage...